David Parkinson, M.D.

Venture Advisor, Menlo Park

David R. Parkinson is a Venture Advisor at New Enterprise Associates (NEA). From 2007 until 2012, Dr. Parkinson served as President and CEO of Nodality, a South San Francisco-based biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy to enable more effective therapeutics development and clinical decision-making. Until October 2007 Dr. Parkinson was Senior Vice President, Oncology Research and Development, at Biogen Idec. At Biogen Idec he oversaw all oncology discovery research efforts and the development of the oncology pipeline. Previously he had served as Vice President, Oncology Development, at Amgen and Vice President, Global Clinical Oncology Development, at Novartis. During his tenures at Amgen and Novartis, Dr. Parkinson was responsible for clinical development activities leading to a series of successful global drug registrations for important cancer therapeutics, including Gleevec, Femara, Zometa, Kepivance, and Vectibix.  Prior to joining industry, Dr. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program. Dr. Parkinson is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee and is a recipient of the FDA's Cody Medal. He has served on the National Cancer Policy Forum of the Institute of Medicine, as a board director of the Ontario Institute for Cancer Research.  He is a past co-chair of the Cancer Steering Committee of the NIH Foundation Biomarkers Consortium and has also served as a member of the FDA's Science Board and as an elected Director on the Board of Directors of the American Association of Cancer Research (AACR). He currently serves on the Boards of the Multiple Myeloma Research Foundation and is the Chairman of the AACR Finance Committee. 

Dr. Parkinson currently serves on the Boards of Threshold Pharmaceuticals and Cerulean Biosciences, both public companies focused on the discovery and development of anti-cancer drugs.  Dr. Parkinson was previously a Director of Facet Biotech, Inc, a public biopharma company which was acquired by Abbott Pharmaceuticals, and until recently also served as a Director on the Board of Ambit Biosciences until its acquisition by Daiichi Sankyo.   

Dr. Parkinson received his medical degree from the University of Toronto.  He completed a Hematology Fellowship at Royal Victoria Hospital at McGill University in Montreal and was a Research Fellow at the New England Medical Center at Tufts University in Boston.  He has held academic positions both at Tufts and at the University of Texas MD Anderson Cancer Center, and is an author of more than 100 publications.